Follow Us
© 2026 Arizent. All rights reserved.
A quiet but significant shift is already underway in workplaces: GLP-1 medications such as Wegovy, Ozempic, and Mounjaro are beginning to reshape not just how people manage weight, but how organizations think about health, productivity, and workplace well-being itself.
For employers, this is not simply a medical development. It is a workplace reality that raises urgent questions about equity, culture, stigma, productivity, and the future design of employee health strategies.
Emelie Fritz is workplace well-being director at Lifesum, where she works at the intersection of health, behaviour change and workplace culture. She regularly comments on employee wellbeing, … Read full bio
For reprint and licensing requests for this article, click here.
Today's complex stressors require clearer access pathways and a company-wide commitment to mental health support.
Advisers who treat absence as a strategic discipline, not a vendor handoff, will have a stronger story to tell and a more valuable role to play.
Employers face another steep rise in healthcare expenses in 2027, prompting a closer look at GLP-1 coverage, pharmacy spending and high-cost conditions.
As costs to treat serious conditions surge, employers must plan how to absorb budget-altering expenses ahead of time.
The 2026 Excellence in Benefits winner is leading the insurance company's efforts to close the preventative care gap and personalize the employee experience.
